Facebook
Twitter
LinkedIn
Instagram
Youtube

Orthocell Limited, achieving a strategic milestone

Team Veye | 22 Jan 2021 ASX - OCC
Orthocell Limited, achieving a strategic milestone

Orthocell Limited (ASX: OCC)

Orthocell receives $2.3m R&D tax incentive refund

Australian-based regenerative medicine company, Orthocell Ltd (ASX: OCC, “Orthocell” or the “Company”), on 20 January 2021 announced that it had received a Research and Development (R&D) Tax Incentive refund of $2,394,397 for the financial year 2019/2020

  • Orthocell receives an R&D Tax Incentive refund of $2.3m
  • Funds will be invested into the Striate+ partnering program, progression of CelGro® nerve repair regulatory approvals, and to advance the development and commercialisation of Ortho-ATI®
  • Orthocell is well positioned to deliver leading regenerative medicine products to the world’s largest health care markets including US, EU and AUS.

(Chart source: TradingView)

Orthocell receives first US CelGro product approval

Orthocell Limited on 14 January 2021 announced that it had achieved FDA 510(k) clearance to market and supply its CelGro collagen medical device for dental bone and tissue regeneration procedures in the US.

  • Orthocell receives FDA 510(k) clearance to market and supply CelGro for dental bone and tissue regeneration procedures
  • Striate+ registered as the new global brand for the CelGro dental bone and tissue regeneration product
  • US, EU and AU market approvals now in place strengthens partnering potential
  • Validates the SMRT™ manufacturing technology and provides a pathway for additional approval in key peripheral nerve repair market.

The FDA 510(k) clearance now allows Orthocell to supply Striate+ in the US dental market, estimated at US$500 million per annum. Striate+ has been approved for supply in dental bone and tissue regeneration procedures such as dental bone defect repair, augmentation around dental implants in immediate and delayed extraction sockets and guided tissue regeneration procedures in intrabony periodontal defects. (Data Source – Company Reports)

 

Veye’s Take

Following the recent US approval of Striate+, the receipt of the R&D tax incentive refund further strengthens the Company’s capital position and enables it to progress the Striate+ partnering program. The approval was received sooner than expected. This is a strategic milestone and a positive step in the pathway to partnering Striate+ in dental GBR indications. The stock was trading in a band, testing the closing levels of $0.450 made in the month of August 2020 repeatedly. The stock managed to close above this level. The upside momentum is seen on the price charts well supported by MACD. RSI is showing slight weakness which is an indication of retracement of the previous bullish candle. The overall uptrend signals upside potential in the stock. Veye maintains a "Hold” on “Orthocell Limited” at the current price of $0.535

Disclaimer

Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.